Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major

Caterina Borgna-Pignatti, Maria Domenica Cappellini, Piero De Stefano, Giovanni Carlo Del Vecchio, Gian Luca Forni, Maria Rita Gamberini, Roberta Ghilardi, Antonio Piga, Maria Antonietta Romeo, Huaqing Zhao, Avital Cnaan

Research output: Contribution to journalArticle

286 Citations (Scopus)

Abstract

Deferoxamine (DFO) therapy has been associated with improved survival of thalassemia patients. However, cardiac disease remains the main cause of death in those patients. In 1995, the oral chelator deferiprone became available for clinical use. We compared the occurrence of cardiac disease in patients treated only with DFO and in those whose therapy was switched to deferiprone during the period of observation, from January 31, 1995, to December 31, 2003. All patients with thalassemia major treated in 7 Italian centers who were born between 1970 and 1993 and who had not experienced a cardiac event prior to January 1995 were included. DFO only was given to 359 patients, and 157 patients received deferiprone for part of the time. A total of 3610 patient-years were observed on DFO and 750 on deferiprone. At baseline, the 2 groups were comparable for age and sex, while ferritin levels were significantly higher in patients switched to deferiprone. Fifty-two cardiac events, including 10 cardiac deaths, occurred during therapy with DFO. No cardiac events occurred during deferiprone therapy or within at least 18 months after the end of it. In the setting of a natural history study, deferiprone therapy was associated with significantly greater cardiac protection than deferoxamine in patients with thalassemia major.

Original languageEnglish
Pages (from-to)3733-3737
Number of pages5
JournalBlood
Volume107
Issue number9
DOIs
Publication statusPublished - May 1 2006

Fingerprint

Deferoxamine
beta-Thalassemia
Morbidity
Mortality
Heart Diseases
Ferritins
Chelating Agents
Therapeutics
deferiprone
Thalassemia
Natural History
Cause of Death
Observation
Survival

ASJC Scopus subject areas

  • Hematology

Cite this

Borgna-Pignatti, C., Cappellini, M. D., De Stefano, P., Del Vecchio, G. C., Forni, G. L., Gamberini, M. R., ... Cnaan, A. (2006). Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood, 107(9), 3733-3737. https://doi.org/10.1182/blood-2005-07-2933

Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. / Borgna-Pignatti, Caterina; Cappellini, Maria Domenica; De Stefano, Piero; Del Vecchio, Giovanni Carlo; Forni, Gian Luca; Gamberini, Maria Rita; Ghilardi, Roberta; Piga, Antonio; Romeo, Maria Antonietta; Zhao, Huaqing; Cnaan, Avital.

In: Blood, Vol. 107, No. 9, 01.05.2006, p. 3733-3737.

Research output: Contribution to journalArticle

Borgna-Pignatti, C, Cappellini, MD, De Stefano, P, Del Vecchio, GC, Forni, GL, Gamberini, MR, Ghilardi, R, Piga, A, Romeo, MA, Zhao, H & Cnaan, A 2006, 'Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major', Blood, vol. 107, no. 9, pp. 3733-3737. https://doi.org/10.1182/blood-2005-07-2933
Borgna-Pignatti C, Cappellini MD, De Stefano P, Del Vecchio GC, Forni GL, Gamberini MR et al. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood. 2006 May 1;107(9):3733-3737. https://doi.org/10.1182/blood-2005-07-2933
Borgna-Pignatti, Caterina ; Cappellini, Maria Domenica ; De Stefano, Piero ; Del Vecchio, Giovanni Carlo ; Forni, Gian Luca ; Gamberini, Maria Rita ; Ghilardi, Roberta ; Piga, Antonio ; Romeo, Maria Antonietta ; Zhao, Huaqing ; Cnaan, Avital. / Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. In: Blood. 2006 ; Vol. 107, No. 9. pp. 3733-3737.
@article{7a8e3750682c4aa69b6d27c6816f18b7,
title = "Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major",
abstract = "Deferoxamine (DFO) therapy has been associated with improved survival of thalassemia patients. However, cardiac disease remains the main cause of death in those patients. In 1995, the oral chelator deferiprone became available for clinical use. We compared the occurrence of cardiac disease in patients treated only with DFO and in those whose therapy was switched to deferiprone during the period of observation, from January 31, 1995, to December 31, 2003. All patients with thalassemia major treated in 7 Italian centers who were born between 1970 and 1993 and who had not experienced a cardiac event prior to January 1995 were included. DFO only was given to 359 patients, and 157 patients received deferiprone for part of the time. A total of 3610 patient-years were observed on DFO and 750 on deferiprone. At baseline, the 2 groups were comparable for age and sex, while ferritin levels were significantly higher in patients switched to deferiprone. Fifty-two cardiac events, including 10 cardiac deaths, occurred during therapy with DFO. No cardiac events occurred during deferiprone therapy or within at least 18 months after the end of it. In the setting of a natural history study, deferiprone therapy was associated with significantly greater cardiac protection than deferoxamine in patients with thalassemia major.",
author = "Caterina Borgna-Pignatti and Cappellini, {Maria Domenica} and {De Stefano}, Piero and {Del Vecchio}, {Giovanni Carlo} and Forni, {Gian Luca} and Gamberini, {Maria Rita} and Roberta Ghilardi and Antonio Piga and Romeo, {Maria Antonietta} and Huaqing Zhao and Avital Cnaan",
year = "2006",
month = "5",
day = "1",
doi = "10.1182/blood-2005-07-2933",
language = "English",
volume = "107",
pages = "3733--3737",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "9",

}

TY - JOUR

T1 - Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major

AU - Borgna-Pignatti, Caterina

AU - Cappellini, Maria Domenica

AU - De Stefano, Piero

AU - Del Vecchio, Giovanni Carlo

AU - Forni, Gian Luca

AU - Gamberini, Maria Rita

AU - Ghilardi, Roberta

AU - Piga, Antonio

AU - Romeo, Maria Antonietta

AU - Zhao, Huaqing

AU - Cnaan, Avital

PY - 2006/5/1

Y1 - 2006/5/1

N2 - Deferoxamine (DFO) therapy has been associated with improved survival of thalassemia patients. However, cardiac disease remains the main cause of death in those patients. In 1995, the oral chelator deferiprone became available for clinical use. We compared the occurrence of cardiac disease in patients treated only with DFO and in those whose therapy was switched to deferiprone during the period of observation, from January 31, 1995, to December 31, 2003. All patients with thalassemia major treated in 7 Italian centers who were born between 1970 and 1993 and who had not experienced a cardiac event prior to January 1995 were included. DFO only was given to 359 patients, and 157 patients received deferiprone for part of the time. A total of 3610 patient-years were observed on DFO and 750 on deferiprone. At baseline, the 2 groups were comparable for age and sex, while ferritin levels were significantly higher in patients switched to deferiprone. Fifty-two cardiac events, including 10 cardiac deaths, occurred during therapy with DFO. No cardiac events occurred during deferiprone therapy or within at least 18 months after the end of it. In the setting of a natural history study, deferiprone therapy was associated with significantly greater cardiac protection than deferoxamine in patients with thalassemia major.

AB - Deferoxamine (DFO) therapy has been associated with improved survival of thalassemia patients. However, cardiac disease remains the main cause of death in those patients. In 1995, the oral chelator deferiprone became available for clinical use. We compared the occurrence of cardiac disease in patients treated only with DFO and in those whose therapy was switched to deferiprone during the period of observation, from January 31, 1995, to December 31, 2003. All patients with thalassemia major treated in 7 Italian centers who were born between 1970 and 1993 and who had not experienced a cardiac event prior to January 1995 were included. DFO only was given to 359 patients, and 157 patients received deferiprone for part of the time. A total of 3610 patient-years were observed on DFO and 750 on deferiprone. At baseline, the 2 groups were comparable for age and sex, while ferritin levels were significantly higher in patients switched to deferiprone. Fifty-two cardiac events, including 10 cardiac deaths, occurred during therapy with DFO. No cardiac events occurred during deferiprone therapy or within at least 18 months after the end of it. In the setting of a natural history study, deferiprone therapy was associated with significantly greater cardiac protection than deferoxamine in patients with thalassemia major.

UR - http://www.scopus.com/inward/record.url?scp=33646407268&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646407268&partnerID=8YFLogxK

U2 - 10.1182/blood-2005-07-2933

DO - 10.1182/blood-2005-07-2933

M3 - Article

C2 - 16373663

AN - SCOPUS:33646407268

VL - 107

SP - 3733

EP - 3737

JO - Blood

JF - Blood

SN - 0006-4971

IS - 9

ER -